Target intelligence / Profile preview

Melatonin receptor type 1B (MT2)

Target
MT2
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

Melatonin receptor type 1B (MT2, encoded by the MTNR1B gene) is a high-affinity G protein-coupled receptor (GPCR) that mediates the physiological actions of melatonin, a hormone primarily secreted by the pineal gland in a circadian pattern. MT2 is predominantly expressed in the retina, brain (specifically the suprachiasmatic nucleus), and peripheral tissues such as pancreatic islets. It plays a critical role in regulating circadian rhythms, sleep-wake cycles, visual processing, and glucose homeostasis. Pharmacological targeting of MT2, typically via non-selective MT1/MT2 agonists like ramelteon, agomelatine, and tasimelteon, is widely utilized to treat insomnia, circadian rhythm sleep disorders, and major depressive disorder. Additionally, genetic variations in MTNR1B (such as the rs10830963 variant) are strongly linked to altered insulin secretion and an increased risk of type 2 diabetes, highlighting its emerging significance in metabolic health and personalized medicine.

Other names
Melatonin receptor 1BMelatonin receptor type 1BMTNR1BMT2Mel-1B-RMel1b receptorMelatonin receptor MEL1B
02

Mechanism of action

Agonist of melatonin receptors MT1 and MT2, modulating circadian rhythms and sleep-wake cycles.

03

Biological functions

Signal transductionCircadian rhythm regulationRegulation of insulin secretionGlucose homeostasisVasodilationVisual processing
04

Disease associations

Sleep disorderDepressionType 2 diabetesObesityCardiovascular disease
05

Safety considerations

Hepatotoxicity (specifically associated with agomelatine)Daytime somnolenceDizzinessImpaired glucose tolerance / risk of type 2 diabetes (especially in carriers of the MTNR1B rs10830963 G-allele risk variant when administered near meals)HyperprolactinemiaDecreased testosterone levelsComplex sleep behaviors (e.g., sleep-driving, sleep-eating)
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

MTNR1B rs10830963 genotypeFasting plasma glucoseDim light melatonin onset (DLMO)Melatonin levels

Beyond the preview

Go deeper on Melatonin receptor type 1B (MT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melatonin receptor type 1B (MT2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call